Navigation Links
SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
Date:5/12/2011

expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these assumptions will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, prolonged impairment of sales from changes in our sales organization, potential difficulties hiring sales personnel with the desired qualifications, revenue shortfalls arising from customer transitions to new products, unpredictability in large customer orders, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.

Contacts:
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400

Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060--Financial Tables to Follow--SERACARE LIFE SCIENCES, INC.STATEMENTS OF OPERATIONS — UNAUDITEDFor the Three Months EndedFor the Six Months EndedMarch 31,March 31,2011201020112010Revenue

$ 11,002,884$ 12,851,370$ 21,465,381$ 24,108,475Cost of revenue

6,603,4637,292,79213,098,07313,633,123Gross profit

4,39
'/>"/>

SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
2. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
5. SeraCare Life Sciences Secures $20 Million Credit Facilities
6. PharmAthene Reports First Quarter 2011 Financial and Operating Results
7. Micell Technologies Reports Preclinical Data for MiStentâ„¢ Drug-Eluting Coronary Stent to be Presented at EuroPCR
8. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
9. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
10. GenVec Reports First Quarter 2011 Financial Results
11. American Oriental Bioengineering Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... LAS VEGAS, NEVADA, Feb. 6 /PRNewswire-FirstCall/ - Diagnostic Imaging,International ... the,Company stock symbol has been cleared for quotation on ... Additionally the Company announced today that the corporate ... Company plans to work diligently to build on its ...
... Feb. 6 The Global Probiotics Council,(GPC), a ... Yakult Honsha,Co., Ltd., announced the Young Investigator Grant ... grants are designed to stimulate,innovative research and to ... United States into the field of probiotics and ...
... to Recognize Exemplary Work, BRIDGEWATER, N.J., Feb. ... nurses, Ortho Biotech Products, L. P.,today announced its ... Oncology Nursing, which honors one of the thousands ... compassion and helpfulness. Last year, more than 200 ...
Cached Biology Technology:Diagnostic Imaging - New Stock Symbol - OTCBB: DIIG 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 4Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... got updated to version 5.0. Proteins are classified,by ... known,pathways. Its main use is probably microarray analysis ... output. Best of,all, its available freely . ... freely in the Nucleic acids research Journal . ...
... An estrogen-like chemical,commonly used to synthesize plastic food ... a specific category of prostate cancer cell,potentially affecting ... to a study published in the January 1 ... to be vulnerable to,exposure to the chemical BPA ...
Cached Biology News:PANTHER Protein Classification System Database 5.0 2PANTHER Protein Classification System Database 5.0 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Biology Products: